Assenagon Asset Management
PETX

Assenagon Asset Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Assenagon Asset Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-196,200
Closed -$706K – 1254
2019
Q1 		$706K Sell
196,200
-21,786
-10% -$94.4K 0.01% 760
2018
Q4 		$1.34M Buy
+217,986
New +$1.33M 0.02% 574

Other funds holding PETX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

Assenagon Asset Management's PETX Position: Q2 2019 in Review

Assenagon Asset Management sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2019, closing a stake of 196,200 shares — an estimated $706K sold.

Assenagon Asset Management first reported a position in PETX in Q4 2018 and held it in 2 quarters. The position peaked at $1.34M in Q4 2018. 103 funds tracked by Wall St. Rank hold PETX as of Q2 2019.

  • Assenagon Asset Management reported no remaining Aratana Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Assenagon Asset Management sold 196,200 Aratana Therapeutics, Inc. shares in Q2 2019, an estimated $706K.
  • Assenagon Asset Management first reported a position in Aratana Therapeutics, Inc. in Q4 2018 and held it in 2 quarters.
  • Assenagon Asset Management's Aratana Therapeutics, Inc. position peaked at $1.34M in Q4 2018.
  • 103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2019.

Based on Assenagon Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.